LLY

1,128.97

-0.68%↓

JNJ

235.88

-1.96%↓

ABBV

221

-2.87%↓

UNH

410.35

+0.51%↑

MRK

114.88

-3.62%↓

LLY

1,128.97

-0.68%↓

JNJ

235.88

-1.96%↓

ABBV

221

-2.87%↓

UNH

410.35

+0.51%↑

MRK

114.88

-3.62%↓

LLY

1,128.97

-0.68%↓

JNJ

235.88

-1.96%↓

ABBV

221

-2.87%↓

UNH

410.35

+0.51%↑

MRK

114.88

-3.62%↓

LLY

1,128.97

-0.68%↓

JNJ

235.88

-1.96%↓

ABBV

221

-2.87%↓

UNH

410.35

+0.51%↑

MRK

114.88

-3.62%↓

LLY

1,128.97

-0.68%↓

JNJ

235.88

-1.96%↓

ABBV

221

-2.87%↓

UNH

410.35

+0.51%↑

MRK

114.88

-3.62%↓

Search

MacroGenics Inc

Suletud

SektorTervishoid

4.11 4.05

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.92

Max

4.24

Põhinäitajad

By Trading Economics

Sissetulek

-23M

-37M

Müük

-20M

21M

Aktsiakasum

-0.58

Kasumimarginaal

-177.011

Töötajad

293

EBITDA

-17M

-32M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+59.85% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

12. aug 2026

Turustatistika

By TradingEconomics

Turukapital

59M

247M

Eelmine avamishind

0.06

Eelmine sulgemishind

4.11

Uudiste sentiment

By Acuity

29%

71%

81 / 342 Pingereas Healthcare

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat